University of Medicine and Dentistry of New Jersey

Rutgers, the State University of New Jersey

Albany Medical College

Matinas Biopharma Nanotechnologies, Inc.

Other

Biodelivery Sciences International, Inc.

The Albany Medical College of Union University

Aquarius Biotechnologies, Inc

Medical College of New Jersey

Biodelivery Sciences, Inc.

Raphael J Mannino

Ruying Lu

Susan Gould-Fogerite

Sara L Krause-Elsmore

David Delmarre

Patrick L Ahl

Gaofeng Shang

Zi Wei Chen

Anthony J Scolpino

Susan G Fogerite

Thomas N Denny

Eleonora Feketeova

James M Oleske

Tuo Jin

David Margolis

Leila Zarif

Gail Goodman-Snitkoff

Doug F Kling

Ignacio Segarra

Sara L Krause

Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.

Cochleates made with soy phosphatidylserine

A cochleate composition is disclosed. Following oral administration of the cochleate composition, the pharmacologically active agent is found at higher concentrations in the tissue relative to plasma. Oral administration of these cochleate compositions also preferentially targets infected or inflamed tissue as compared to tissue in a healthy subject. The cochleate composition contains a size-regulating agent that reduces cochleate particle size, such as a lipid-anchored polynucleotide, a lipid-anchored sugar, a lipid-anchored polypeptide, or a bile salt (such as oxycholate or deoxycholate). Also disclosed are methods of treatment using the cochleate composition and methods of increasing the concentration of a pharmacologically active agent in an infected tissue relative to the concentration of the pharmacologically active agent in the plasma or the tissue of a healthy subject.

Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent

The present application is directed to a cochleate composition including one or more cochleates and at least two antifungal compounds selected from amphotericin B, 5-flucytosine, fluconazole, ketoconazole, ravuconazole, albaconazole, itraconazole, posaconazole, isavuconazole and/or voriconazole. Methods of using the antifungal cochleate formulations are also disclosed.

Encholeated antifungal compounds for central nervous system delivery and treatment ofinfections

Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.

Encochleation methods, cochleates and methods of use

The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for later addition of cargo moieties are also contemplated.

Geodate delivery vehicles

Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions.

Cochleate compositions directed against expression of proteins

The present invention is directed to siRNA-cochleate compositions that include a siRNA that is associated with a cochleate and a positively charged amphiphile. The present invention also includes methods for making and using the compositions provided herein.

Amphiphilic nucleotide cochleate compositions and methods of using the same

A process for producing a small-sized, lipid-based cochleate. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca or Zn , forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules.

Hydrogel-isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules

An integrative DNA vector and one or more viral proteins having affinity for DNA are packaged in cochleate precipitates. The integrative DNA vector contains one or more therapeutic nucleotide sequences that are preferably positioned between DNA substrates for the proteins. Upon contact with a lipid bilayer of a target cell, the cochleate vector structure delivers one or more of the therapeutic nucleotide sequences and one or more proteins to the interior of the target cell. Upon entry into the cell, the proteins facilitate the integration of the therapeutic nucleotide sequence into the genome of the host cell.

Integrative protein-DNA cochleate formulations and methods for transforming cells

Growing community of inventors

Glen Gardner, NJ, United States of America

Raphael J Mannino